Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Lymphoma 5Central Nervous System Neoplasms 5Neuroblastoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Opsoclonus-Myoclonus Syndrome 2Meningeal Carcinomatosis 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Intraocular Lymphoma 2Burkitt Lymphoma 2beta-Thalassemia 1Wilms Tumor 1Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Testicular Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neurotoxicity Syndromes 1Neurofibromatosis 1 1Neoplasms 1Neoplasm, Residual 1

Interventions

Temozolomide 3gadobenic acid 2XENP 1595 2Trastuzumab 2Sodium Chloride 2Dexmedetomidine 2Cancer Vaccines 2Adjuvants, Immunologic 2veliparib 1tucatinib 1tipifarnib 1sagopilone 1pembrolizumab 1interferon gamma-1b 1glutathione pegylated liposomal doxorubicin 1gadoteridol 1elacestrant 1abemaciclib 1Tissue Banks 1Saline Solution 1Rituximab 1Radiotherapy 1Radiation 1RAD1901 1Oncolytic Virotherapy 1Interferon-gamma 1Immunotherapy 1Dasatinib 1Craniotomy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Diseases × Rituximab × CNS × Clear all
NCT01596127 2018-05-24

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 7 charts
CNSOther hematologic neoplasm

Central Nervous System Diseases, Leukemia, Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡